Tuesday, July 30, 2013
Pfizer settles U.S. marketing case dating to Wyeth conduct
People walk past the Pfizer Inc. headquarters in New York, January 31, 2013.
Credit: Reuters/Brendan McDermid
WASHINGTON |
(Reuters) - Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.
Wyeth trained its national Rapamune sales force to promote the use of the drug in situations not approved by the U.S. Food and Drug Administration, the department said in a statement.
(Reporting by David Ingram; Editing by Gerald E. McCormick)
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers. Five Filters recommends: 'You Say What You Like, Because They Like What You Say' - http://www.medialens.org/index.php/alerts/alert-archive/alerts-2013/731-you-say-what-you-like-because-they-like-what-you-say.html
